Staphylococcus aureus (MRSA) is one of the most dangerous bacteria, causing numerous infections in humans worldwide. It has received particular attention due to its ability to develop antibiotic resistance, making it difficult to treat. In this article, we will examine what MRSA is, why it poses a threat to human health, and how phage therapy can help combat this bacterium.

Why is MRSA so dangerous?

Staphylococcus aureus, specifically the MRSA (methicillin-resistant Staphylococcus aureus) strain, is a member of the Staphylococcus family of bacteria . This microorganism is distinguished by its ability to cause serious infections and its resistance to standard antibiotics. MRSA can cause a variety of illnesses, from common purulent wounds to more serious infections such as pneumonia or sepsis.

The bacterium was named "golden" because it is capable of forming yellow colonies on nutrient media, and "methicillin-resistant" means that this strain is able to resist the action of the antibiotic methicillin, one of the most common in the fight against bacteria.

This pathogen can be dangerous because it rapidly reproduces and produces toxins that damage human tissue and organs. However, the worst part is its resistance to most traditional antibiotics, making treatment of infections caused by this bacterium extremely difficult.

How does MRSA infection occur?

MRSA can be transmitted in a variety of ways, but the most common is contact with contaminated surfaces or people. The bacteria can enter the body through microscopic pores in the skin caused by cuts or scrapes. The bacteria can also be transmitted through the air, especially in hospitals or medical facilities where patients have weakened immune systems.

Staphylococcus aureus is a common cause of hospital-acquired infections. Infection can also occur through unsterile medical instruments, catheters, and dressings.

However, there is another route of transmission - through contact with people who are carriers of this bacteria, especially when using shared hygiene items or during sports where there is contact with the skin of another person.

Diseases caused by MRSA and their symptoms

MRSA can cause a variety of serious illnesses. One of the most common is a skin infection, manifesting as a red, pus-filled rash. Additionally, this bacterial strain can cause the following serious conditions:

• Pneumonia is a lung infection that causes coughing, difficulty breathing, and fever.

• Sepsis is a dangerous condition that develops when an infection spreads throughout the body, causing inflammation of the blood.

• Joint and bone infections often occur due to a break in the skin or medical procedures.

• Heart infections - In severe cases, MRSA can infect the heart valves, leading to serious problems with the cardiovascular system.

Symptoms of the disease can vary depending on the organ affected by the bacteria. Typically, they include fever, pain, inflammation, and swelling in the affected areas.

Standard treatment for Staphylococcus aureus

Antibiotics are traditionally used to treat infections caused by Staphylococcus aureus. However, with the development of resistance to methicillin and other traditional drugs, treatment effectiveness has significantly decreased. Many MRSA strains have become resistant to antibiotics such as penicillin and ampicillin.

Modern treatments include the use of vancomycin and other powerful antibiotics, but the problem is that even these drugs do not always provide guaranteed results.

Phage therapy research against MRSA

Phage therapy is a promising method for combating methicillin-resistant Staphylococcus aureus (MRSA), and numerous studies are currently underway to evaluate its effectiveness. Below are specific studies demonstrating the potential of using bacteriophages to treat MRSA infections.

Research at the University of Illinois

The effectiveness of bacteriophages against MRSA was studied in laboratory conditions. Scientists used phages specifically selected to combat a specific strain of MRSA and demonstrated their ability to successfully kill the bacteria even under conditions where conventional antibiotics were ineffective. The phages also reduced the pathogen's ability to develop new infections. ( pubmed.ncbi.nlm.nih.gov )

Phage therapy research at the Georgian University

Scientists conducted a study examining the effects of phages on patients with severe hospital-acquired MRSA infections. They used combination therapy—antibiotics combined with phages. The results showed a significant reduction in bacterial load and an improvement in clinical symptoms within just a few days of starting phage treatment.

Experimental treatment for MRSA at a clinic in Poland

In 2019, a clinical trial was conducted in Poland in which phages were administered to patients with severe MRSA infections as part of their treatment. The bacteriophage therapy resulted in a significant improvement in the patients' condition, a reduction in the size of purulent wounds, and a decrease in the level of bacteria in the blood.

Bacteriophages against methicillin-resistant strains of Staphylococcus aureus

This study, conducted by researchers from the Bogomolets National Medical University and Kyiv City Clinical Hospital No. 4, examined the susceptibility of clinical isolates of S. aureus, including methicillin-resistant strains (MRSA), to Pyofag® polyvalent bacteriophage. Results showed that 95% of the strains were susceptible, and its use in the treatment of furunculosis caused by MRSA yielded positive results without adverse effects. ( bacteriophages.info )

Phage therapy for bacterial prostatitis

This paper describes a clinical case of chronic bacterial prostatitis in a 33-year-old man diagnosed with methicillin-resistant Staphylococcus aureus (MRSA), among other pathogens. After ineffective antibiotic treatment, the patient sought treatment at the G. Eliava Phage Therapy Center in Tbilisi, Georgia, where he received phage therapy, which resulted in improvement.
( bacteriophages.info )

Bacteriophage endolysins against atopic dermatitis

A randomized, double-blind, placebo-controlled Phase I/IIa study of endolysin XZ.700, specific for Staphylococcus aureus, is planned in patients with mild to moderate atopic dermatitis. The objective is to evaluate the drug's efficacy and safety. (bacteriophages.info )

Phage cocktail against multidrug-resistant staphylococcus in diabetic foot

A study by Australian scientists examined the effectiveness of the AB-SA01 phage cocktail, containing three anti-S. aureus phage strains , in a mouse model of diabetic foot infection with multidrug-resistant S. aureus. The results showed that the phage cocktail reduced the microbial load and promoted wound healing without side effects. ( bacteriophages.info )

Research shows that bacteriophages are a promising solution for treating MRSA, especially in the face of growing antibiotic resistance. Phage therapy is currently undergoing rapid development and may soon become a standard treatment for Staphylococcus aureus infections.